Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Allogene Therapeutics Inc...

    NASDAQ: ALLO · Real-Time Price · USD
    1.36
    0.02 (1.49%)
    At close: Jun 16, 2025, 3:59 PM
    1.34
    -1.47%
    After-hours: Jun 16, 2025, 07:29 PM EDT
    1.49%
    Bid 1.34
    Market Cap 297.47M
    Revenue (ttm) -22K
    Net Income (ttm) -252.32M
    EPS (ttm) -1.22
    PE Ratio (ttm) -1.11
    Forward PE -1.42
    Analyst Buy
    Ask 1.37
    Volume 1,612,919
    Avg. Volume (20D) 3,282,693
    Open 1.36
    Previous Close 1.34
    Day's Range 1.32 - 1.41
    52-Week Range 0.86 - 3.78
    Beta 0.31

    About ALLO

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ALLO
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ALLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +8.55%
    Allogene Therapeutics shares are trading higher af... Unlock content with Pro Subscription
    1 month ago
    -15.68%
    Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.
    news image

    4 days ago · zacks.com

    Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?

    Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

    news image

    5 days ago · https://www.defenseworld.net

    Squarepoint Ops LLC Sells 168,152 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

    Squarepoint Ops LLC cut its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 89.2% during the fourth quarter, according to the company in its most recent disclosu...

    news image

    1 week ago · zacks.com

    All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy

    Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    2 weeks ago · seekingalpha.com

    Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

    Allogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, espe...

    news image

    2 weeks ago · seekingalpha.com

    Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

    Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data readouts. The company's financial position remains stable, supported by a strong...

    news image

    1 month ago · zacks.com

    Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

    news image

    1 month ago · zacks.com

    Allogene's Q1 Earnings In Line With Estimates, Sales Nil

    ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.

    news image

    1 month ago · seekingalpha.com

    Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

    Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer Davi...

    news image

    2 months ago · zacks.com

    FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

    The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.

    Add to Watchlist